Biocon Limited — Important, 23-07-2025: General Updates

Biocon Biologics has launched Nepexto®, its biosimilar to Enbrel® (Etanercept), in Australia, partnering with Generic Health. This strategic expansion broadens access to a crucial treatment for autoimmune diseases like rheumatoid arthritis. Nepexto® has already achieved widespread adoption across Europe since 2020. This move strengthens Biocon Biologics' global immunology offering and signals their intent to capture new markets, positioning the company for potential growth in its biosimilars segment.